“This is part of our commitment to delivering Smarter AI for All—developing and deploying technology that can empower ...

In the last two years, two drugs have been federally approved to slow the onset of Alzheimer's disease in its early stages, ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) ...

The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) announced key resources and philanthropic capital to reshape scientific research fields and advance better ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

As the global leader in advanced MRI post-processing solutions, Cortechs.ai is proud to highlight the unmatched capabilities of NeuroQuant® ARIA, the first FDA-cleared tool to offer processing for ...

Australia is on the brink of a healthcare revolution driven by DNA science that will save lives and prevent disease – but top ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Leah, 27, was visiting the house to oversee the renovations ahead of putting it on the market when she noticed the shed was ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...